pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›neladalkib
drug · small molecule
save

neladalkib

pre_registrationupdated 6mo ago
by $NUVL Nuvalent, Inc.🔗 ChEMBL
community read0 votes

Small molecule drug with a maximum clinical stage of Phase 1 2, with 1 investigational indication.

indications

indications
NSCLC

all catalysts(0)

nothing on the calendar yet

Trials studying neladalkib

  • phase3Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCrecruitingn=450
  • phase2A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)recruitingn=840

News(9)

  • FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
    The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
    biopharma_dive · 19h ago
  • GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
    Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.
    biospace · 20h ago
  • GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer
    GSK has secured a US accelerated approval for its oral lung cancer drug neladalkib, one of two assets at the heart of its $10.6 billion purchase of oncology drugmaker Nuvalent earlier this ...
    endpoints · 1d ago
  • ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up
    GSK’s cancer R&D chief has suggested the latest slice of early-stage data on its B7-H4-directed antibody-drug conjugate (ADC) has “reinforce[d] our belief in the asset,” as the therapy races throug…
    fiercebiotech · 28d ago
  • Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
    Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
    biopharma_dive · 3mo ago
  • GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
    GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…
    fiercebiotech · 3mo ago
  • GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
    Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…
    biospace · 3mo ago
  • GSK lung cancer drug gets speedy approval following $10.6B deal
    The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
    biopharma_dive · 3mo ago
  • GSK boosts cancer pipeline with $11B Nuvalent buyout
    The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.
    biopharma_dive · 5mo ago
generic
neladalkib
indication
Non-Small Cell Lung Cancer
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?